Literature DB >> 32165620

Hidradenitis suppurativa.

Robert Sabat1, Gregor B E Jemec2, Łukasz Matusiak3, Alexa B Kimball4, Errol Prens5, Kerstin Wolk6.   

Abstract

Hidradenitis suppurativa (HS; also designated as acne inversa) is a chronic inflammatory disorder, which affects the intertriginous skin and is associated with numerous systemic comorbidities. The estimated prevalence of HS is ~1% in most studied countries. Typically starting in early adulthood, cutaneous inflamed nodules, abscesses and pus-discharging tunnels develop in axillary, inguinal, gluteal and perianal body sites. The comorbidities of HS include metabolic and cardiovascular disorders, which contribute to reduced life expectancy. A genetic predisposition, smoking, obesity and hormonal factors are established aetiological factors for HS. Cutaneous changes seem to start around hair follicles and involve activation of cells of the innate and adaptive immune systems, with pivotal roles for pro-inflammatory cytokines such as tumour necrosis factor, IL-1β and IL-17. The unrestricted and chronic immune response eventually leads to severe pain, pus discharge, irreversible tissue destruction and scar development. HS has profound negative effects on patients' quality of life, which often culminate in social withdrawal, unemployment, depression and suicidal thoughts. The therapeutic options for HS comprise antibiotic treatment, neutralization of tumour necrosis factor and surgical intervention together with lifestyle modification. Nevertheless, there is an enormous need for awareness of HS, understanding of its pathogenesis and novel treatments.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32165620     DOI: 10.1038/s41572-020-0149-1

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  225 in total

1.  Hidradenitis suppurativa markedly decreases quality of life and professional activity.

Authors:  Łukasz Matusiak; Andrzej Bieniek; Jacek C Szepietowski
Journal:  J Am Acad Dermatol       Date:  2010-04       Impact factor: 11.527

2.  A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark.

Authors:  P Theut Riis; L Thorlacius; E Knudsen List; G B E Jemec
Journal:  Br J Dermatol       Date:  2017-02-09       Impact factor: 9.302

3.  Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study.

Authors:  Inge E Deckers; Farida Benhadou; Marjolein J Koldijk; Veronique Del Marmol; Barbara Horváth; Jurr Boer; Hessel H van der Zee; Errol P Prens
Journal:  J Am Acad Dermatol       Date:  2016-10-25       Impact factor: 11.527

4.  High Prevalence of Back Pain and Axial Spondyloarthropathy in Patients with Hidradenitis Suppurativa.

Authors:  Sylke Schneider-Burrus; Ellen Witte-Haendel; Demetrios Christou; Benedetta Rigoni; Robert Sabat; Gerd Diederichs
Journal:  Dermatology       Date:  2016-09-21       Impact factor: 5.366

5.  Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.

Authors:  Julia Shlyankevich; Allison J Chen; Grace E Kim; Alexandra B Kimball
Journal:  J Am Acad Dermatol       Date:  2014-10-14       Impact factor: 11.527

6.  Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa.

Authors:  Kerstin Wolk; Katarzyna Warszawska; Conny Hoeflich; Ellen Witte; Sylke Schneider-Burrus; Katrin Witte; Stefanie Kunz; Annette Buss; Hans Joachim Roewert; Markus Krause; Ansgar Lukowsky; Hans-Dieter Volk; Wolfram Sterry; Robert Sabat
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

7.  Hidradenitis suppurativa associated with spondyloarthritis -- results from a multicenter national prospective study.

Authors:  Pascal Richette; Anna Molto; Manuel Viguier; Karen Dawidowicz; Gilles Hayem; Aude Nassif; Daniel Wendling; François Aubin; Frédéric Lioté; Hervé Bachelez
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 8.  Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.

Authors:  Ditte Marie Lindhardt Saunte; Gregor Borut Ernst Jemec
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

9.  Increased prevalence of metabolic syndrome in patients with acne inversa.

Authors:  Robert Sabat; Akewit Chanwangpong; Sylke Schneider-Burrus; Deborah Metternich; Georgios Kokolakis; Agata Kurek; Sandra Philipp; Daniela Uribe; Kerstin Wolk; Wolfram Sterry
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

10.  Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa.

Authors:  J R Ingram; S Jenkins-Jones; D W Knipe; C L I Morgan; R Cannings-John; V Piguet
Journal:  Br J Dermatol       Date:  2018-02-22       Impact factor: 11.113

View more
  55 in total

1.  Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System.

Authors:  Georgios Kokolakis; Kerstin Wolk; Sylke Schneider-Burrus; Stefanie Kalus; Sebastian Barbus; Susana Gomis-Kleindienst; Robert Sabat
Journal:  Dermatology       Date:  2020-07-01       Impact factor: 5.366

Review 2.  Botulinum toxin type A for the management of hidradenitis suppurativa.

Authors:  Huanhuan Qu; Lin Gao
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Microbial Isolates and Association with Disease Severity and Quality of Life in Individuals with Hidradenitis Suppurativa: An Observational Study.

Authors:  Sarah Lou Bailey; Christian Buckingham; Hector Maxwell-Scott; Ellie Rashidghamat; Felicity J Ferguson; Helena Malhomme de la Roche; Simon D Goldenberg
Journal:  Skin Appendage Disord       Date:  2022-03-17

Review 4.  TRP Channels as Molecular Targets to Relieve Endocrine-Related Diseases.

Authors:  Yusheng Liu; Yihan Lyu; Hongmei Wang
Journal:  Front Mol Biosci       Date:  2022-04-28

Review 5.  [Pathogenesis of hidradenitis suppurativa/acne inversa].

Authors:  G Nikolakis; G Kokolakis; K Kaleta; K Wolk; R Hunger; R Sabat; C C Zouboulis
Journal:  Hautarzt       Date:  2021-07-06       Impact factor: 0.751

Review 6.  [Topical and novel device-based therapies for mild hidradenitis suppurativa].

Authors:  G Nikolakis; E von Stebut
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

7.  Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort.

Authors:  Kelsey R van Straalen; Errol P Prens; Gonneke Willemsen; Dorret I Boomsma; H H van der Zee
Journal:  JAMA Dermatol       Date:  2020-12-01       Impact factor: 10.282

8.  Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients.

Authors:  Sylke Schneider-Burrus; Athanasia Tsaousi; Sebastian Barbus; Johannes Huss-Marp; Katrin Witte; Kerstin Wolk; Björn Fritz; Robert Sabat
Journal:  Front Med (Lausanne)       Date:  2021-04-27

Review 9.  Insights from γ-Secretase: Functional Genetics of Hidradenitis Suppurativa.

Authors:  Gautham Vellaichamy; Peter Dimitrion; Li Zhou; David Ozog; Henry W Lim; Wilson Liao; Iltefat H Hamzavi; Qing-Sheng Mi
Journal:  J Invest Dermatol       Date:  2021-04-07       Impact factor: 7.590

10.  Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.

Authors:  Kristina Navrazhina; John W Frew; Patricia Gilleaudeau; Mary Sullivan-Whalen; Sandra Garcet; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2021-02-03       Impact factor: 14.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.